Showing results (1-10 of 281) with videos related to
Sort By:
Pageof 29
Methods in Molecular Biology (Clifton, N.J.)|September 15, 2010
De novo drug designMarkus Hartenfeller, Gisbert SchneiderCurrent Pharmaceutical Design|March 13, 2010
Concepts and applications of "natural computing" techniques in de novo drug and peptide designJan A Hiss, Markus Hartenfeller, Gisbert SchneiderChemical Biology & Drug Design|June 20, 2008
Concept of combinatorial de novo design of drug-like molecules by particle swarm optimizationMarkus Hartenfeller, Ewgenij Proschak, Andreas Schüller, et al.Trends in Biotechnology|November 14, 2008
Voyages to the (un)known: adaptive design of bioactive compoundsGisbert Schneider, Markus Hartenfeller, Michael Reutlinger, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|July 22, 2010
Multistep virtual screening for rapid and efficient identification of non-nucleoside bacterial thymidine kinase inhibitorsJohannes Zander, Markus Hartenfeller, Volker Hähnke, et al.Chemical Communications (Cambridge, England)|April 2, 2015
Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulatorsTiago Rodrigues, Yen-Chu Lin, Markus Hartenfeller, et al.Journal of Chemical Information and Modeling|November 15, 2011
A collection of robust organic synthesis reactions for in silico molecule designMarkus Hartenfeller, Martin Eberle, Peter Meier, et al.Plos Computational Biology|February 24, 2012
DOGS: reaction-driven de novo design of bioactive compoundsMarkus Hartenfeller, Heiko Zettl, Miriam Walter, et al.Journal of Chemical Information and Modeling|April 20, 2012
Probing the bioactivity-relevant chemical space of robust reactions and common molecular building blocksMarkus Hartenfeller, Martin Eberle, Peter Meier, et al.Angewandte Chemie (International Ed. in English)|November 21, 2012
Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leadsBirgit Spänkuch, Sarah Keppner, Lisa Lange, et al.Pageof 29